Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Moshe Ornstein MD

Moshe C. Ornstein MD

Genitourinary Medical Oncologist, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Dr. Moshe Ornstein is a genitourinary medical oncologist at the Cleveland Clinic Taussig Cancer Institute. He attended graduate school at Columbia University, where he received a degree in biotechnology studying tumor immunology. Following graduate school, he attended medical school at SUNY Stony Brook. His completed his internal medicine residency and hematology/oncology fellowship at the Cleveland Clinic.

Dr. Ornstein's clinical practice and research are focused on cancers of the genitourinary system, specifically kidney, bladder, and prostate cancer. He has published multiple research articles and presented his research at a variety of national meetings, including the annual meeting of the American Society of Clinical Oncology (ASCO) and ASCO Genitourinary Cancers Symposium. He is actively involved in multiple clinical trials.

Disclosures

Dr. Ornstein reports the following disclosure: Consulting/Advisory Role: Pfizer, Eisai, BMS; Speaking: BMS, Exelixis.

Recent Contributions to PracticeUpdate:

  1. Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma
  2. ASCO GU 2016: Dr. Fred Saad’s Prostate Cancer Year in Review—Part 1: Screening and Active Surveillance
  3. ASCO GU 2016: Dr. Fred Saad’s Prostate Cancer Year in Review—Part 3: ADT, Chemotherapy in Hormone-Sensitive Disease, and New Options in mCRPC
  4. ASCO GU 2016: Dr. Fred Saad’s Prostate Cancer Year in Review—Part 2: Importance of Local Therapy
  5. Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy
  6. IKCS 2015: mRCC Tumor Burden Reduced With TKI Dose Escalation
  7. Dr. Mary-Ellen Taplin’s “Do Not Miss” GU Oncology Highlights of 2014
  8. Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer
  9. The Utility of Biopsy and Role of Cryoablation vs Partial Nephrectomy
  10. Blood Pressure After Acute Intracerebral Hemorrhage

Most Read This Week

Recently Updated